Welcome to Dwaey, specifically on Gliclazide page.
This medicine contains important and useful components, as it consists of
Gliclazide is available in the market in concentration.
Gliclazide
Before initiating gliclazide, it is important to consult with a healthcare provider to ensure that it is the appropriate medication for your specific health needs. Patients with type 1 diabetes, hypersensitivity to sulfonylureas, or severe renal or hepatic impairment should avoid using gliclazide. It should not be used in individuals with diabetic ketoacidosis. Careful monitoring is required for patients with a history of cardiovascular disease, as sulfonylureas may increase the risk of heart-related complications. The drug is also contraindicated during pregnancy and breastfeeding due to potential risks to the fetus or infant. Hypoglycemia is a key risk associated with gliclazide, especially when used in combination with other antidiabetic medications. Patients should regularly monitor their blood glucose levels and adhere to prescribed doses. Always seek professional medical guidance before starting or adjusting this medication to ensure safe and effective use.
Gliclazide is primarily indicated for the management of type 2 diabetes mellitus. It is prescribed when blood glucose levels cannot be controlled through diet and exercise alone. Gliclazide helps lower blood sugar by stimulating the pancreas to release insulin. It is typically used in combination with lifestyle modifications, such as diet and exercise, and may be combined with other oral hypoglycemic agents if additional blood glucose control is needed. The medication is particularly effective in individuals with residual pancreatic beta-cell function, making it unsuitable for type 1 diabetes, where insulin production is impaired. Gliclazide can be used as part of a comprehensive approach to managing type 2 diabetes and maintaining stable blood glucose levels.
Gliclazide is contraindicated in several situations to ensure patient safety. It should not be used in individuals with type 1 diabetes mellitus, as it is ineffective in this condition where there is a complete lack of insulin production. It is also contraindicated in patients with hypersensitivity to sulfonylureas or any of the ingredients in gliclazide. People with severe renal or hepatic impairment should not use this medication due to the risk of drug accumulation and potential toxicity. Additionally, gliclazide should not be used in patients experiencing diabetic ketoacidosis, as it does not address this serious condition. Pregnant and breastfeeding women should avoid gliclazide, as it can pose risks to the fetus or infant. Careful use is also advised for elderly patients, as they may be more susceptible to adverse effects like hypoglycemia.
Common side effects of gliclazide include hypoglycemia (low blood sugar), which can present as symptoms such as dizziness, sweating, shaking, confusion, or, in severe cases, loss of consciousness or seizures. Other gastrointestinal side effects may include nausea, vomiting, or indigestion. Weight gain is also a reported side effect in some individuals. Skin reactions, such as rash or itching, can occur as well. While rare, more severe side effects may include blood disorders like leukopenia (low white blood cell count) or thrombocytopenia (low platelet count). Long-term use may increase the risk of cardiovascular events, particularly in patients with pre-existing heart conditions. Patients should regularly monitor blood glucose levels and report any unusual symptoms, such as prolonged dizziness or difficulty concentrating, to their healthcare provider immediately.
3
Gliclazide is a sulfonylurea that works by stimulating insulin secretion from the pancreas. It binds to specific receptors on the ATP-sensitive potassium channels (K_ATP channels) on pancreatic beta cells. This binding causes the channels to close, leading to depolarization of the cell membrane. The depolarization opens voltage-dependent calcium channels, allowing calcium to enter the cells, which triggers the release of insulin. The released insulin helps to reduce blood glucose levels by facilitating the uptake of glucose into the cells. Additionally, gliclazide may improve the first-phase insulin response in individuals with type 2 diabetes, contributing to better overall glucose control. This mechanism is effective as long as the pancreas still has some ability to produce insulin.
Gliclazide can interact with various medications and substances, which may impact its effectiveness or cause adverse effects. Medications that increase blood sugar levels, such as corticosteroids, thiazide diuretics, and certain oral contraceptives, may reduce the effectiveness of gliclazide. On the other hand, drugs that lower blood sugar, including insulin and other oral antidiabetic agents, can increase the risk of hypoglycemia when taken together with gliclazide. Alcohol consumption can enhance the drug’s hypoglycemic effect, leading to an increased risk of low blood sugar, especially if alcohol is consumed in large quantities. Additionally, gliclazide may interact with drugs that affect liver enzymes, such as rifampin or barbiturates, potentially altering its metabolism. It is essential to inform your healthcare provider about all medications and supplements you are taking to prevent harmful interactions.
The typical starting dose of gliclazide for adults is 40 mg to 80 mg once daily, taken with breakfast or the first main meal. Depending on the individual’s blood glucose response, the dose may be adjusted, and the usual maintenance dose ranges from 80 mg to 320 mg per day. It is generally divided into one or two doses, taken with meals to reduce the risk of gastrointestinal upset. In some cases, the dose may be gradually increased to achieve optimal blood glucose control. The maximum recommended dose is 320 mg per day. Patients should be monitored regularly to assess efficacy and prevent hypoglycemia. It is important to follow your healthcare provider’s instructions to ensure proper dosing.
Gliclazide is generally not recommended for use in children due to a lack of sufficient safety and efficacy data in pediatric populations. In rare cases, if prescribed for a child, the dose would be determined by the child’s healthcare provider based on their specific needs, age, and weight. However, because type 2 diabetes in children is uncommon and the use of gliclazide in children is not well studied, healthcare providers may explore alternative treatment options. Always consult with a healthcare provider before administering gliclazide to a child to ensure safety and proper dosing.
It is crucial that patients consult their healthcare provider before starting any medication, including gliclazide, to ensure it is appropriate for their condition and to prevent potential complications. Regular monitoring and adherence to prescribed guidelines are essential for effective treatment and to minimize side effects.
Gliclazide should be used with caution in patients with renal impairment. In mild to moderate renal insufficiency, the usual adult dose may be used, but close monitoring of blood glucose levels is essential. In patients with severe renal dysfunction, gliclazide may not be appropriate due to the increased risk of drug accumulation and potential for hypoglycemia. Dose adjustments should be made based on kidney function, and alternative treatments may be considered for individuals with severe renal impairment. Always consult with a healthcare provider for personalized recommendations regarding dosing in patients with kidney issues.
Not available in a medicine form yet